Adenosine A2A receptor mediated protective effect of 2-(6-cyano-1-hexyn-1-yl)adenosine on retinal ischaemia/reperfusion damage in rats.

The British Journal of Ophthalmology
Takashi KonnoNorimichi Nakahata

Abstract

To determine the effect of 2-(6-cyano-1-hexyn-1-yl)adenosine (2-CN-Ado), an adenosine A2A receptor agonist, on retinal ischaemia/reperfusion damage in rats. Retinal ischaemia/reperfusion damage was induced by elevating the intraocular pressure of one eye to 130 mm Hg for 60 minutes and returning it to normal. 7 days later, retinal ischaemia/reperfusion damage was histologically quantified by measuring the thickness of retinal layers. Intraocular pressure was measured by pressure transducer. Retinal ischaemia/reperfusion caused cell loss in the ganglion cell layer and thinning of the inner plexiform and nuclear layer. Both ocular topical and intravenous administration of 2-CN-Ado caused a reduction of retinal ischaemia/reperfusion damage. A selective A2A receptor antagonist, 1,3,7-trimethyl-8-(3-chlorostyryl) xanthine (CSC), but not a selective A1 receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), or a selective A2B receptor antagonist, alloxazine, reduced the protective effect of 2-CN-Ado. While ocular topical administration of 2-CN-Ado caused a sustained reduction of intraocular pressure, intravenous administration of 2-CN-Ado showed a transient ocular hypotensive effect. These results suggest that 2-CN-Ado atten...Continue Reading

References

Oct 1, 1991·Cellular and Molecular Neurobiology·C Blazynski, M T Perez
Jan 1, 1988·Journal of Ocular Pharmacology·S C BraunagelG C Chiou
Jun 1, 1995·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·M WeberJ A Sahel
Jun 1, 1993·Pediatric Research·J M Gidday, T S Park
Apr 1, 1997·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·T T LamM O Tso
Jul 9, 1999·Vision Research·G J GhiardiS Roth
Jul 17, 2003·Journal of Postgraduate Medicine·S KaushikJ Ram
Feb 10, 2004·Progress in Retinal and Eye Research·Neville N OsborneJosé Melena
Feb 27, 2004·European Journal of Pharmacology·Takashi KonnoNorimichi Nakahata

❮ Previous
Next ❯

Citations

Dec 12, 2013·Journal of Neuroinflammation·Steven F AbcouwerDavid A Antonetti
Dec 20, 2015·Translational Research : the Journal of Laboratory and Clinical Medicine·Maria H MadeiraAna Raquel Santiago
Jan 24, 2007·Life Sciences·Takashi KonnoNorimichi Nakahata
Aug 19, 2014·Mediators of Inflammation·Ana R SantiagoCatarina A Gomes
Jan 9, 2014·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Arivalagan MuthusamyDavid A Antonetti
Dec 18, 2013·Pharmacological Reviews·Geoffrey Burnstock, Vera Ralevic
Jan 1, 2010·Expert Review of Clinical Pharmacology·Simon MantellMike Trevethick
Feb 29, 2020·Pharmacology & Therapeutics·Ana Raquel SantiagoAntónio Francisco Ambrósio
Mar 18, 2021·Cellular and Molecular Neurobiology·D Pereira-FigueiredoK C Calaza
Aug 18, 2021·Expert Opinion on Therapeutic Targets·Puneet Agarwal, Renu Agarwal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.